NANOVIRICIDES, INC.

NANOVIRICIDES, INC.

NanoViricides, Inc. was founded and incorporated in Delaware, with its origins in research conducted by Dr. Anil Diwan, who holds a PhD and MBA and serves as the company's President and Chairman. The firm is headquartered in Shelton, Connecticut, and focuses on the development of broad-spectrum antiviral therapeutics using a nanomicelle platform that delivers active drug payloads directly to viral particles. The company's strategy centers on advancing multiple drug candidates through preclinical and clinical stages, targeting viruses including influenza, HIV, HSV-1, and COVID-19. A key asset is NV-387, a drug candidate for respiratory syncytial virus and COVID-19, which has shown efficacy in animal models. The firm has not disclosed partnerships or co-investors in its pipeline development, and its geographic footprint is limited to the United States, with a focus on U.S. regulatory pathways. As of the latest financial filings, NanoViricides has raised capital through public offerings, with no disclosed AUM or deployment figures—it is a development-stage biotech, not an asset manager. The company's team includes approximately 10 professionals, with key executives comprising Dr. Diwan, CEO Milton Boniuk, and CFO and Treasurer Dr. Meeta Vyas. No additional offices or adjacent vehicles have been reported; the firm is a standalone corporation. A structural differentiator of NanoViricides is its exclusive focus on a single technology platform—nanoviricide therapy—applied across multiple virus families. This contrast with broader biotech firms that diversify across modalities. The company's governance is concentrated under Dr. Diwan's leadership, with a small board and no succession plan publicly visible, which introduces key-person risk typical of early-stage drug developers.